CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs

Abstract Background Limited data exist about the use, efficacy, and prognostic factors influencing outcome when CyberKnife is used to treat dogs with intracranial neoplasia. Objectives To determine the prognosis and associated prognostic factors for dogs that were imaged, determined to have primary...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gabrielle L. Carter, Gregory K. Ogilvie, Lenore A. Mohammadian, Phillip J. Bergman, Rachel P. Lee, David R. Proulx
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	brain cancer dog radiation Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/9ce5457c713945ce83d4c791b2b11f85
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9ce5457c713945ce83d4c791b2b11f85
record_format	dspace
spelling	oai:doaj.org-article:9ce5457c713945ce83d4c791b2b11f852021-11-30T17:01:04ZCyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs1939-16760891-664010.1111/jvim.16086https://doaj.org/article/9ce5457c713945ce83d4c791b2b11f852021-05-01T00:00:00Zhttps://doi.org/10.1111/jvim.16086https://doaj.org/toc/0891-6640https://doaj.org/toc/1939-1676Abstract Background Limited data exist about the use, efficacy, and prognostic factors influencing outcome when CyberKnife is used to treat dogs with intracranial neoplasia. Objectives To determine the prognosis and associated prognostic factors for dogs that were imaged, determined to have primary intracranial tumors, and treated with CyberKnife radiotherapy. Animals Fifty‐nine dogs treated with CyberKnife radiotherapy for primary intracranial tumors. Methods Retrospective medical record review of cases from January 2010 to June 2016. Data extracted from medical records included signalment, weight, seizure history, tumor location, tumor type (based on imaging), gross tumor volume, planned tumor volume, treatment dates, radiation dose, recurrence, date of death, and cause of death. Results The median progression‐free interval (PFI) was 347 days (range 47 to 1529 days), and the median survival time (MST) was 738 days (range 4 to 2079 days). Tumor location was significantly associated with PFI when comparing cerebrum (median PFI 357 days; range 47‐1529 days) versus cerebellum (median PFI 97 days; range 97‐168 days) versus brainstem (median PFI 266 days; range 30‐1484 days), P = .03. Additionally, the presumed tumor type was significantly associated with MST (P < .001). Conclusions and Clinical Importance Use of Cyberknife and SRT might improve MST, compared with RT, in dogs with intracranial neoplasia.Gabrielle L. CarterGregory K. OgilvieLenore A. MohammadianPhillip J. BergmanRachel P. LeeDavid R. ProulxWileyarticlebraincancerdogradiationVeterinary medicineSF600-1100ENJournal of Veterinary Internal Medicine, Vol 35, Iss 3, Pp 1480-1486 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	brain cancer dog radiation Veterinary medicine SF600-1100
spellingShingle	brain cancer dog radiation Veterinary medicine SF600-1100 Gabrielle L. Carter Gregory K. Ogilvie Lenore A. Mohammadian Phillip J. Bergman Rachel P. Lee David R. Proulx CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs
description	Abstract Background Limited data exist about the use, efficacy, and prognostic factors influencing outcome when CyberKnife is used to treat dogs with intracranial neoplasia. Objectives To determine the prognosis and associated prognostic factors for dogs that were imaged, determined to have primary intracranial tumors, and treated with CyberKnife radiotherapy. Animals Fifty‐nine dogs treated with CyberKnife radiotherapy for primary intracranial tumors. Methods Retrospective medical record review of cases from January 2010 to June 2016. Data extracted from medical records included signalment, weight, seizure history, tumor location, tumor type (based on imaging), gross tumor volume, planned tumor volume, treatment dates, radiation dose, recurrence, date of death, and cause of death. Results The median progression‐free interval (PFI) was 347 days (range 47 to 1529 days), and the median survival time (MST) was 738 days (range 4 to 2079 days). Tumor location was significantly associated with PFI when comparing cerebrum (median PFI 357 days; range 47‐1529 days) versus cerebellum (median PFI 97 days; range 97‐168 days) versus brainstem (median PFI 266 days; range 30‐1484 days), P = .03. Additionally, the presumed tumor type was significantly associated with MST (P < .001). Conclusions and Clinical Importance Use of Cyberknife and SRT might improve MST, compared with RT, in dogs with intracranial neoplasia.
format	article
author	Gabrielle L. Carter Gregory K. Ogilvie Lenore A. Mohammadian Phillip J. Bergman Rachel P. Lee David R. Proulx
author_facet	Gabrielle L. Carter Gregory K. Ogilvie Lenore A. Mohammadian Phillip J. Bergman Rachel P. Lee David R. Proulx
author_sort	Gabrielle L. Carter
title	CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs
title_short	CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs
title_full	CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs
title_fullStr	CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs
title_full_unstemmed	CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs
title_sort	cyberknife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/9ce5457c713945ce83d4c791b2b11f85
work_keys_str_mv	AT gabriellelcarter cyberknifestereotacticradiotherapyfortreatmentofprimaryintracranialtumorsindogs AT gregorykogilvie cyberknifestereotacticradiotherapyfortreatmentofprimaryintracranialtumorsindogs AT lenoreamohammadian cyberknifestereotacticradiotherapyfortreatmentofprimaryintracranialtumorsindogs AT phillipjbergman cyberknifestereotacticradiotherapyfortreatmentofprimaryintracranialtumorsindogs AT rachelplee cyberknifestereotacticradiotherapyfortreatmentofprimaryintracranialtumorsindogs AT davidrproulx cyberknifestereotacticradiotherapyfortreatmentofprimaryintracranialtumorsindogs
_version_	1718406461445373952

CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs

Ejemplares similares